| 1 |
35596703 | Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma. | 2022 May 21 |
1 |
| 2 |
33904373 | Predicting candidate therapeutic drugs for sepsis-induced acute respiratory distress syndrome based on transcriptome profiling. | 2021 Dec |
2 |
| 3 |
34638362 | Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy. | 2021 Sep 29 |
1 |
| 4 |
32599901 | Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. | 2020 Jun 24 |
1 |
| 5 |
30760286 | TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. | 2019 Feb 13 |
1 |
| 6 |
31216997 | Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. | 2019 Jun 19 |
1 |
| 7 |
29728799 | Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. | 2018 Jul |
5 |
| 8 |
28813519 | Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. | 2017 |
2 |
| 9 |
27557643 | Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. | 2016 Aug 24 |
1 |
| 10 |
26100858 | TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. | 2015 Sep |
1 |
| 11 |
24492650 | Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. | 2014 Apr |
4 |
| 12 |
25406834 | Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. | 2014 Nov 18 |
1 |
| 13 |
21768308 | Translational control of TOP2A influences doxorubicin efficacy. | 2011 Sep |
2 |
| 14 |
21188112 | Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients. | 2010 Aug 20 |
1 |
| 15 |
19417146 | Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. | 2009 May |
6 |
| 16 |
19620488 | Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. | 2009 Aug 20 |
2 |
| 17 |
18574145 | Topoisomerase levels determine chemotherapy response in vitro and in vivo. | 2008 Jul 1 |
4 |
| 18 |
16502015 | Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. | 2006 Aug |
4 |
| 19 |
16935488 | Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. | 2006 Nov |
1 |
| 20 |
17089011 | DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. | 2006 Dec |
1 |
| 21 |
15765123 | Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. | 2005 May |
1 |